We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ProMIS Neurosciences Inc | TSX:PMN | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.00 | 5.85 | 8.75 | 0 | 00:00:00 |
The corrected URL is: www.virtualshareholdermeeting.com/PMN2023
Please use the corrected URL to access the Annual Meeting of Shareholders, which begins on June 29, 2023 at 9:30am Eastern Time. All other information included in the Definitive Proxy Statement remains unchanged.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.
To learn more, visit us at www.promisneurosciences.com.
For Investor Relations please contact:
For Investor Relations, please contact: Stern Investor RelationsSuzanne Messere, Managing Directorsuzanne.messere@sternir.comTel. 212 698-8801
1 Year ProMIS Neurosciences Chart |
1 Month ProMIS Neurosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions